The International Society on Thrombosis and Haemostasis (ISTH) will recognize its landmark 50th anniversary as the leader in the field of thrombosis and hemostasis at the ISTH 2019 Congress from July 6-10 in Melbourne, Australia. Under the congress theme of “Research, Discovery, Outcomes,” more than 5,000 experts from over 90 countries in the field will convene at the Melbourne Convention Exhibition Centre (MCEC) to present the latest basic, translational and clinical research and discuss the diagnostic and therapeutic advances in bleeding and clotting disorders.
“We are very excited to welcome experts to Melbourne from around the world to attend the leading scientific event in the field of thrombosis, hemostasis and vascular biology,” said ISTH 2019 Congress President Prof. Robert Medcalf . “The ISTH 2019 Congress features a range of groundbreaking research, innovative offerings and scientific advances to improve the lives of patients worldwide. Furthermore, the congress offers the perfect platform for early career professionals and others to obtain the connections and knowledge needed to advance their career.”
This year, more than 2,136 scientific abstracts from more than 75 countries were submitted by clinicians, scientists, academics and students for ISTH 2019. Abstracts cover trending scientific topics such as arterial thromboembolism, coagulation and anticoagulation, diagnostics and OMICs, fibrinolysis and proteolysis, hemophilia and bleeding disorders including transfusion, immunothrombosis and vascular biology, nursing, pediatrics, platelets and megakaryocytes, platelet disorders, prothrombotic stress, venous thromboembolism and women’s health.
Opportunity to Preview the Latest Scientific Highlights
The official ISTH 2019 press briefing will take place on Tuesday, July 9, from 11:00 a.m. – 12:00 p.m. and will provide an overview of the latest key scientific evidence and findings presented at the congress.
Moderated by Prof. Philip Hogg from the University of Sydney in Sydney, Australia, the press briefing will cover relevant topics such as treatment of acute venous thromboembolism in children, subcutaneous prophylaxis in hemophilia, screening of deep vein thrombosis, use of filters in severely injured patients, gene therapy and more. In addition to the press briefing, in-depth presentations on the scientific highlights featured at the ISTH 2019 press briefing will take place at the following times during the congress:
Late Breaking Abstracts, Session on Monday, July 8 from 10:45 a.m. – 12:00 p.m.
Subcutaneous Prophylaxis with the Anti-TFPI Monoclonal Antibody Concizumab in Hemophilia A and Hemophilia A/B with Inhibitors: Phase 2 Trial Results
— Presentation Number: LB 01.1
— Presenting Author: Jan Astermark
First-in-human Evidence of Durable Therapeutic Efficacy and Safety of AAV Gene Therapy Over Three-years with Valoctocogene Roxaparvovec for Severe Haemophilia A (BMN 270-201 Study)
— Presentation Number: LB 01.2
— Presenting Author: K. John Pasi
A Multicenter Trial of Vena Cava Filters in Severely-Injured Patients
— Presentation Number: LB 01.3
— Presenting Author: Kwok-Ming Ho
Magnetic Resonance Direct Thrombus Imaging Can Safely Rule Out Recurrent Ipsilateral Deep Vein Thrombosis of the Leg – The Theia Study
— Presentation Number: LB 01.4
— Presenting Author: Lisette F. van Dam
Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Children
— Presentation Number: LB 01.5
— Presenting Author: Christoph Male
For the ISTH 2019 full abstracts supplement, click here .
